Macguire Cheswick & Tuttle Investment Counsel LLC Maintains Position in Pfizer, Inc. (PFE)

Macguire Cheswick & Tuttle Investment Counsel LLC maintained its position in Pfizer, Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,098 shares of the biopharmaceutical company’s stock at the end of the second quarter. Macguire Cheswick & Tuttle Investment Counsel LLC’s holdings in Pfizer were worth $238,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Northstar Group Inc. increased its stake in Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares during the period. River Wealth Advisors LLC increased its stake in Pfizer by 0.3% during the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares during the period. Meridian Wealth Management LLC increased its stake in Pfizer by 0.5% during the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after acquiring an additional 57 shares during the period. Stone House Investment Management LLC increased its stake in Pfizer by 0.9% during the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 66 shares during the period. Finally, Telemus Capital LLC boosted its holdings in shares of Pfizer by 0.5% in the 2nd quarter. Telemus Capital LLC now owns 17,888 shares of the biopharmaceutical company’s stock valued at $601,000 after purchasing an additional 92 shares in the last quarter. Hedge funds and other institutional investors own 69.36% of the company’s stock.

Pfizer, Inc. (NYSE PFE) opened at $35.30 on Tuesday. The stock has a market capitalization of $209,697.67, a price-to-earnings ratio of 14.07, a P/E/G ratio of 2.49 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer, Inc. has a 12-month low of $30.51 and a 12-month high of $36.78.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the company earned $0.61 EPS. equities research analysts anticipate that Pfizer, Inc. will post 2.59 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.

A number of brokerages have weighed in on PFE. BMO Capital Markets reaffirmed a “buy” rating and issued a $39.00 target price on shares of Pfizer in a report on Friday. J P Morgan Chase & Co set a $39.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Jefferies Group LLC set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a report on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a report on Wednesday, November 1st. Finally, UBS AG set a $38.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $38.48.

In other news, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the transaction, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 374,621 shares of company stock valued at $12,796,098. Corporate insiders own 0.06% of the company’s stock.

WARNING: This report was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.chaffeybreeze.com/2017/11/14/macguire-cheswick-tuttle-investment-counsel-llc-maintains-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply